Form 4: Structure Therapeutics Inc. Executive Ma Yingli Reports Stock and Option Awards

Chief Technology Officer Ma Yingli reports acquisition of restricted stock units and stock options in Structure Therapeutics Inc.

Summary

• On March 15, 2025, Ma Yingli, Chief Technology Officer of Structure Therapeutics Inc., reported transactions involving the company's securities.
• Ma Yingli acquired 63,810 ordinary shares through the grant of restricted stock units (RSUs).
• Ma Yingli was also granted an option to purchase 155,040 ordinary shares at an exercise price of $7.02.
• Following these transactions, Ma Yingli directly owns 155,040 derivative securities and 100,539 ordinary shares.
• The RSUs vest 1/4th annually starting March 1, 2025, contingent upon continued service.
• The stock options vest 1/4th on March 1, 2026, with the remaining shares vesting in 36 equal monthly installments, also subject to continued service.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. The sentiment is neutral to positive as it indicates ongoing commitment from key personnel.

Positives

• The grant of RSUs and stock options to the Chief Technology Officer aligns their interests with the long-term success of Structure Therapeutics Inc.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continued service, incentivizing long-term commitment to the company.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, such as the one described (1/4th annually or a combination of annual and monthly vesting), are typical to ensure continued service and alignment with company goals.
• The specific number of shares and exercise price would be determined based on factors like the executive's role, performance, and the company's overall compensation strategy, compared to similar roles at companies like Amgen, Regeneron, or Vertex.

Stakeholder Impact

• Shareholders may view the grants as a positive sign, indicating the company's commitment to retaining key talent.
• Employees may see this as a positive signal regarding the company's financial health and future prospects.

Key Dates